<DOC>
	<DOCNO>NCT00868166</DOCNO>
	<brief_summary>The purpose assay ass safety efficacy TRO19622 330 mg QD add-on therapy riluzole 50 mg bid treatment patient suffer ALS , compare placebo , assess 18-month survival rate .</brief_summary>
	<brief_title>Safety Efficacy TRO19622 add-on Therapy Riluzole Versus Placebo Treatment Patients Suffering From Amyotrophic Lateral Sclerosis ( ALS )</brief_title>
	<detailed_description>A stand alone treatment TRO19622 acceptable ethical reason . Riluzole approve widely use ALS treatment European community , Japan USA . Therefore , study , TRO19622 assess add-on riluzole patient suffer ALS . At start study , patient randomize one two group : TRO19622 ( 330 mg QD placebo ( day ) . Each treatment administer 18 month double-blind condition . The product evaluation administer patient receive standard care ALS , include riluzole . Riluzole dosage ( 50 mg bid ) must stable well tolerate least one month prior inclusion study . After double-blind period , open-label administration TRO19622 allow safety survival assessment efficacy result available . A separate open-label protocol write 6 month randomization last patient study .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Riluzole</mesh_term>
	<criteria>Patients sporadic familial Amyotrophic Lateral Sclerosis Patients clinical diagnosis laboratorysupported probable , probable , definite ALS accord modify El Escorial criteria8 . Have sign Informed Consent participate trial study related procedure take place . Be age &gt; 18 ( exclusive ) &lt; 80 year ( inclusive ) . If female , lactating , negative pregnancy test agree use effective method birth control . Onset ALS Symptoms ( weakness ) 6 month ( inclusive ) less 36 month ( inclusive ) . Slow vital capacity ( SVC ) , measure three time , one measure &gt; /= 70 % predict . Treated riluzole stable dose 50 mg bid least 30 day enrolment . Tracheostomy , invasive ventilation , non invasive positive pressure ventilation ( NIPPV ) . Gastrostomy . Evidence major psychiatric disorder clinically evident dementia . Diagnosis neurodegenerative disease addition ALS . Have current medication could interfere TRO19622 pharmacokinetics : tamoxifene . Have current medication could interfere TRO19622 absorption ezetimibe , bile salt chelators ( cholesteramine ) , fibrates , phytosterols , niacin ( vitamin B3 ) , fish oil . Have current medication lipid lower agent statin . Known hypersensitivity component study drug . Patients know intolerance contraindication riluzole . Have recent history ( within previous 6 month ) current evidence alcohol drug abuse . Have concurrent unstable disease involve system eg , carcinoma basal cell carcinoma , cardiac dysrhythmia , myocardial infarction , clinical ECG sign myocardial ischemia , cardiac insufficiency , angina symptom , current symptom Coronary Artery Disease , condition opinion Investigator would make patient unsuitable study participation . . In Germany : Have cardiac dysrhythmia , myocardial infarction , clinical ECG sign myocardial ischemia , cardiac insufficiency , angina symptom , current symptom Coronary Artery Disease cardiovascular illness know identified screen inclusion visit , concurrent unstable disease involve system eg , carcinoma basal cell carcinoma condition opinion Investigator would make patient unsuitable study participation . Having baseline QTc ( Bazett ) &gt; 450 msec male &gt; 470 msec female . Patients know hepatitis B/C HIV positive serology . Be pregnant female lactating . Have renal impairment define blood creatinine &gt; 1:5 X upper limit normal . Have hepatic impairment and/or liver enzyme ( ALAT ASAT ) &gt; 3 X ULN . Hemostasis disorder current treatment oral anticoagulant . Be possibly dependent Investigator Sponsor ( eg , include , limited , affiliated employee ) . Participated investigational drug therapy study non approve medication , within previous 3 month . Patients without Social Security Insurance ( France ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Amyotrophic Lateral Sclerosis</keyword>
	<keyword>TRO19622</keyword>
	<keyword>Trophos</keyword>
</DOC>